Assessment | Biopsychology | Comparative | Cognitive | Developmental | Language | Individual differences | Personality | Philosophy | Social |
Methods | Statistics | Clinical | Educational | Industrial | Professional items | World psychology |

Biological: Behavioural genetics · Evolutionary psychology · Neuroanatomy · Neurochemistry · Neuroendocrinology · Neuroscience · Psychoneuroimmunology · Physiological Psychology · Psychopharmacology (Index, Outline)

Armodafinil chemical structure

IUPAC name
CAS number
ATC code


Chemical formula {{{chemical_formula}}}
Molecular weight 273.351
Metabolism Hepatic, including CYP3A4 and other pathways
Elimination half-life 12-15 hrs
Excretion Urine (as metabolites)
Pregnancy category C
Legal status Schedule IV (USA)
Routes of administration Oral

Armodafinil (Nuvigil®) is an eugeroic drug produced by the pharmaceutical company Cephalon Inc., currently in the process of receiving Food and Drug Administration (FDA) approval. Armodafinil is the r-enantiomer of modafinil, so is expected to act in a similar manner, with similar effects. However, it acts for a longer duration of time than modafinil. Cephalon hopes to soon release the longer-lasting Nuvigil (R-modafinil) as a "truly once-a-day" wakefulness medication. In 2006, the FDA sent Cephalon an "approvable letter" for Nuvigil, pending agreement on the final product labeling. Upon approval, it is expected to be classified as a Schedule IV controlled substance.

See alsoEdit

External linksEdit

This page uses Creative Commons Licensed content from Wikipedia (view authors).
Community content is available under CC-BY-SA unless otherwise noted.